Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Keywords HCC molecular subtype liver cell lineages atezolizumab bevacizumab immunotherapy mechanisms of response and resistance Introduction Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the fourth most lethal.1 Combination immunotherapy with atezolizumab and bevacizumab has become a new standard of care as the first-line therapy for unresectable HCC by demonstrating strong antitumor activity in an initial phase 1b study (GO30140)2 and subsequently superior...
Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers. Globally, HCC is the third leading cause of cancer deaths, although it ranks sixth in the worldwide incidence of cancer, attesting to the poor general prognosis [1,2].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
